drugset / Trial / NCT01058616
Dose-escalation Study of LTX-315 in Patients With a Transdermally Accessible Tumour
Phase 1
Completed
14 enrolled
Lytix Biopharma AS
Karolinska University Hospital · collabOslo University Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
The study will evaluate the safety profile for LTX-315 a lytic-peptide that has shown effect in animal models to kill cancer tumours when injected directly in to the tumour. The study will also monitor the immunological response in the body after injection of LTX-315.
Timeline
- Start
- 2010-01
- Primary completion
- 2013-01
- Completion
- 2013-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RUXOTEMITIDE | Peptide | 5 mg/ml | Other |
| Subject | RUXOTEMITIDE | Peptide | 70 mg/ml | Other |
Indications
No indication recorded.